pinatuzumab vedotin (RG7593) - Roche
Polivy (polatuzumab vedotin) - Roche, Seattle Genetics
Roche: Q1 2014 Sales Results (Roche) - Apr 16, 2014 - Anticipated presentation of interim data from P2 ROMULUS RG7596 vs. RG7593 trial for non-Hodgkin's lymphoma at ASCO (May 30 - Jun 03, 2014); Anticipated initiation of P1 trial for refractory solid tumors in Apr 2014 
Anticipated P2 data • Anticipated trial initiation date Oncology
http://www.roche.com/investors/ir_agenda/q1-2014.htm
 
Apr 16, 2014
 
.
 
7d73beab-800f-4454-9c59-1519bd5aa369.jpg